Verrica Pharmaceuticals VRCA
NASDAQ VRCA
$3.91 +0.39 (+11.08%)
At close: Nov 11, 2026 · 4:00 PM EST

Verrica Pharmaceuticals (VRCA) Gains from Sales and Divestitures (2023 - 2025)

Updated

Verrica Pharmaceuticals (VRCA) reported Gains from Sales and Divestitures of -$246,000 for FY2025, compared with -$83,000 in FY2024.

Analysis

Verrica Pharmaceuticals (VRCA) Gains from Sales and Divestitures (2023 - 2025) Analysis & Trends

  • According to Business Quant data, Gains from Sales and Divestitures came in at -$83,000 in FY2024 and -$2.54 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn
10 Verrica Pharmaceuticals 60.47 Mn -22.58 Mn 5.43 Mn
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 -68,000.00
Dec 31, 2024 58,000.00
Dec 31, 2023 -2.48 Mn
Sep 30, 2023 -61,000.00
API Access

Verrica Pharmaceuticals Gains from Sales and Divestitures API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=gains-from-sales-and-divestitures&ticker=VRCA&period=max&api_key=YOUR_API_KEY